The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

New research from Florida State University suggests depression screening in patients with coronary artery disease (CAD) is especially crucial, because those individuals tend to have higher rates of morbidity and mortality.

Despite being performed in an older population with more cardiovascular comorbidities, transcatheter aortic valve replacement (TAVR) demonstrated similarly low rates of postoperative stroke and mortality compared with surgical aortic valve replacement (SAVR) in a study of patients with previous strokes.

Although survival after congenital heart surgery is improving, patients who receive procedures for even mild defects have long-term mortality rates at least three times higher than their counterparts in the general population, according to a U.S.-based registry study published in the Journal of the American College of Cardiology.

Patients who suffer minor ischemic stroke or a transient ischemic attack (TIA) can lower the risk for a major stroke within 90 days by taking both clopidogrel and aspirin, according to a study published online May 16 in The New England Journal of Medicine.